← Eichor
Study identifier: NCT07301866 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Study Testing an Improved Dose of UM171 to Help Make Cord Blood Transplants More Effective and Safe.

Condition: Acute Leukemia, High Risk · Myelodysplastic Syndromes, High Risk · Hematologic Malignancy Requiring an Allogeneic Hematopoietic Stem Cell Transplant Lacking a Donor  ·  Sponsor: Ciusss de L'Est de l'Île de Montréal

PhasePhase 1/Phase 2
Planned participants7
Who can joinAll sexes, 18 Years to 67 Years
Healthy volunteersNo

About this study

This clinical study is testing a new way to improve stem cell transplants for adults with high-risk blood cancers, such as leukemia or myelodysplasia, who do not have a suitable donor. The transplant uses stem cells from umbilical cord blood that have been expanded in the lab using a molecule called UM171. Previous studies showed that UM171 helps these cells grow and work better, leading to faster blood count recovery and fewer complications. In this study, researchers are testing whether increasing the dose of UM171 during the lab expansion process can make the transplant less toxic. The hypothesis is that using a higher dose of UM171 to expand cord blood stem cells will help patients recover blood counts faster after transplant by improving the growth and function of the cells. This may lead to better immune recovery, fewer infections, shorter hospital stays, and improved overall outcomes. Only seven patients will be enrolled, and they will be followed for one year after their transplant.

This description comes directly from the study's public registry record.

Talk to the study team

Sandra Cohen, Dr.  ·  514-252-3404  ·  sandra.cohen.med@ssss.gouv.qc.ca

Always discuss trial participation with your own doctor first.

Locations (1)

Hôpital Maisonneuve-RosemontMontreal, Quebec, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07301866